Patents by Inventor Paul J. Bertics
Paul J. Bertics has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8569043Abstract: A method for differentiating between a post-translationally modified peptide and a peptide contained in a sample, comprising: (a) contacting the sample with a peptide attachment surface to create a peptidized surface, wherein the sample includes at least one functional group; (b) contacting the peptidized surface with a recognition reagent that selectively binds or forms a complex with the post-translationally modified peptide in the sample to provide an incubated surface; and (c) contacting a liquid crystal with the incubated surface and detecting presence of post-translationally modified peptide in the sample with the liquid crystal.Type: GrantFiled: July 15, 2010Date of Patent: October 29, 2013Assignee: Wisconsin Alumni Research FoundationInventors: Nicholas L. Abbott, Brian H. Clare, Paul J. Bertics
-
Patent number: 7960131Abstract: A method of assaying nucleotide receptor P2X7 pore activity in white blood cells contained within a mixed cell sample is provided comprising labeling white blood cells with a white blood cell-specific label; depolarizing the labeled white blood cells with an isotonic depolarizing solution; contacting the labeled white blood cells with dye and a P2X7 agonist in an amount sufficient to activate P2X7 pore activity; contacting the labeled white blood cells with a divalent cation in an amount sufficient to deactivate P2X7 pore activity; and analyzing dye uptake whereby P2X7 pore activity is quantified by the amount of dye taken up in labeled white blood cells treated with the P2X7 agonist relative to labeled white blood cells in the absence of said P2X7 agonist, said P2X7 pore activity being corrected for sample age and by subtraction of P2X7 pore activity contributed by nonviable white blood cells.Type: GrantFiled: June 3, 2008Date of Patent: June 14, 2011Assignee: Wisconsin Alumni Research FoundationInventors: Loren C. Denlinger, Kirk J. Hogan, Paul J. Bertics, Kathleen Schell
-
Publication number: 20110053280Abstract: A method for differentiating between a post-translationally modified peptide and a peptide contained in a sample, comprising: (a) contacting the sample with a peptide attachment surface to create a peptidized surface, wherein the sample includes at least one functional group; (b) contacting the peptidized surface with a recognition reagent that selectively binds or forms a complex with the post-translationally modified peptide in the sample to provide an incubated surface; and (c) contacting a liquid crystal with the incubated surface and detecting presence of post-translationally modified peptide in the sample with the liquid crystal.Type: ApplicationFiled: July 15, 2010Publication date: March 3, 2011Applicant: Wisconsin Alumni Research FoundationInventors: Nicholas L. Abbott, Brian H. Clare, Paul J. Bertics
-
Patent number: 7795007Abstract: A method for differentiating between a post-translationally modified peptide and a peptide contained in a sample, comprising: (a) contacting the sample with a peptide attachment surface to create a peptidized surface, wherein the sample includes at least one functional group; (b) contacting the peptidized surface with a recognition reagent that selectively binds or forms a complex with the post-translationally modified peptide in the sample to provide an incubated surface; and (c) contacting a liquid crystal with the incubated surface and detecting presence of post-translationally modified peptide in the sample with the liquid crystal.Type: GrantFiled: June 20, 2005Date of Patent: September 14, 2010Assignee: Wisconsin Alumni Research FoundationInventors: Nicholas L. Abbott, Brian H. Clare, Paul J. Bertics
-
Patent number: 7560243Abstract: A method of rapidly assaying nucleotide receptor P2X7 pore activity in white blood cells contained within a blood sample. A method according to the invention includes the steps of: (a) labeling the white blood cells with a white blood cell-specific label; (b) depolarizing the labeled white blood cells with an isotonic depolarizing solution; (c) contacting the labeled white blood cells with a dye and a P2X7 agonist in an amount sufficient to activate nucleotide receptor P2X7 pore activity; (d) contacting the labeled white blood cells with a divalent cation in an amount sufficient to deactivate nucleotide receptor P2X7 pore activity; and (e) analyzing dye uptake in labeled white blood cells whereby nucleotide receptor P2X7 pore activity is quantified by the amount of dye taken up in labeled white blood cells treated with P2X7 agonist relative to labeled white blood cells in the absence of P2X7 agonist.Type: GrantFiled: April 20, 2004Date of Patent: July 14, 2009Assignee: Wisconsin Alumni Research FoundationInventors: Loren C. Denlinger, Kirk J. Hogan, Paul J. Bertics, Kathleen Schell
-
Publication number: 20090053204Abstract: A method of assaying nucleotide receptor P2X7 pore activity in white blood cells contained within a mixed cell sample is provided comprising labeling white blood cells with a white blood cell-specific label; depolarizing the labeled white blood cells with an isotonic depolarizing solution; contacting the labeled white blood cells with dye and a P2X7 agonist in an amount sufficient to activate P2X7 pore activity; contacting the labeled white blood cells with a divalent cation in an amount sufficient to deactivate P2X7 pore activity; and analyzing dye uptake whereby P2X7 pore activity is quantified by the amount of dye taken up in labeled white blood cells treated with the P2X7 agonist relative to labeled white blood cells in the absence of said P2X7 agonist, said P2X7 pore activity being corrected for sample age and by subtraction of P2X7 pore activity contributed by nonviable white blood cells.Type: ApplicationFiled: June 3, 2008Publication date: February 26, 2009Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Loren C. Denlinger, Kirk J. Hogan, Paul J. Bertics, Kathleen Schell
-
Publication number: 20040253650Abstract: A method of rapidly assaying nucleotide receptor P2X7 pore activity in white blood cells contained within a blood sample. A method according to the invention includes the steps of: (a) labeling the white blood cells with a white blood cell-specific label; (b) depolarizing the labeled white blood cells with an isotonic depolarizing solution; (c) contacting the labeled white blood cells with a dye and a P2X7 agonist in an amount sufficient to activate nucleotide receptor P2X7 pore activity; (d) contacting the labeled white blood cells with a divalent cation in an amount sufficient to deactivate nucleotide receptor P2X7 pore activity; and (e) analyzing dye uptake in labeled white blood cells whereby nucleotide receptor P2X7 pore activity is quantified by the amount of dye taken up in labeled white blood cells treated with P2X7 agonist relative to labeled white blood cells in the absence of P2X7 agonist.Type: ApplicationFiled: April 20, 2004Publication date: December 16, 2004Applicant: Wisconsin Alumni Research FoundationInventors: Loren C. Denlinger, Kirk J. Hogan, Paul J. Bertics, Kathleen Schell
-
Patent number: 6531499Abstract: Peptoid compounds of Formula I and Formula II are disclosed The compounds are useful in the treatment of matrix metalloproteinase-mediated disorders.Type: GrantFiled: July 23, 2001Date of Patent: March 11, 2003Assignee: Wisconsin Alumni Research FoundationInventors: Donald T. Witiak, Paul J. Bertics, Yingsheng Zhang
-
Publication number: 20020032347Abstract: Peptiod compounds of Formula I and Formula II are disclosed 1Type: ApplicationFiled: July 23, 2001Publication date: March 14, 2002Inventors: Donald T. Witiak, Deanne B. Witiak, Paul J. Bertics, Yingsheng Zhang
-
Patent number: 6294694Abstract: Peptoid compounds of Formula I and Formula II are disclosed The compounds are useful in the treatment of matrix metalloproteinase-mediated disorders.Type: GrantFiled: June 4, 1999Date of Patent: September 25, 2001Assignee: Wisconsin Alumni Research FoundationInventors: Donald T. Witiak, Paul J. Bertics, Yingsheng Zhang
-
Patent number: 5624913Abstract: A method for reducing the TNF-alpha in mammals with cerebral malaria comprising the administration of 2-methylthio-ATP or 2-chloro-ATP.Type: GrantFiled: August 30, 1994Date of Patent: April 29, 1997Assignee: Wisconsin Alumni Research FoundationInventors: Richard A. Proctor, Paul J. Bertics
-
Patent number: 5516762Abstract: A method of treating a mammal exposed to endotoxin in order to reduce the detrimental effects of said endotoxin, comprising administering to said mammal a therapeutically effective amount of a 2-halo-adenosine nucleotide analog. 2-Cloro-ATP is the preferred species of the 2-halo-adenosine nucleotide. The nucleotide used in this treatment inhibits lipo-polysaccharide-induced GTPase activity.Type: GrantFiled: October 15, 1993Date of Patent: May 14, 1996Assignee: Wisconsin Alumni Research FoundationInventors: Paul J. Bertics, Richard A. Proctor
-
Patent number: 5492898Abstract: A method of treating mammals to reduce the deleterious effects of endotoxin and endotoxic shock mediators comprising administering a therapeutic amount of a 2-alkylthio-adenosine-5'-nucleotide. The preferred compound is 2-methylthio-adenosine-5'-triphosphate. The nucleotide used in this treatment inhibits lipopolysaccharide-induced GTPase activity.Type: GrantFiled: October 15, 1993Date of Patent: February 20, 1996Assignee: Wisconsin Alumni Research FoundationInventors: Paul J. Bertics, Richard A. Proctor